Skip to main content
placeholder image

NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).

Journal Article


Abstract


UOW Authors


  •   Tome, Wolfgang (external author)

Publication Date


  • 2019

Citation


  • Gondi, V., Deshmukh, S., Brown, P. D., Wefel, J. S., Tome, W., Armstrong, T., . . . Kachnic, L. A. (2019). NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).. Journal of Clinical Oncology, 37(15_suppl), 2009. doi:10.1200/jco.2019.37.15_suppl.2009

Web Of Science Accession Number


Start Page


  • 2009

End Page


  • 2009

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Tome, Wolfgang (external author)

Publication Date


  • 2019

Citation


  • Gondi, V., Deshmukh, S., Brown, P. D., Wefel, J. S., Tome, W., Armstrong, T., . . . Kachnic, L. A. (2019). NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).. Journal of Clinical Oncology, 37(15_suppl), 2009. doi:10.1200/jco.2019.37.15_suppl.2009

Web Of Science Accession Number


Start Page


  • 2009

End Page


  • 2009

Volume


  • 37

Issue


  • 15_suppl

Place Of Publication